Janku Filip

30PUBLICATIONS
139CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesBasic pharmacologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

Filip Janku, Opeyemi A Jegede, Shannon L Puhalla

|Jul 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

Blessie Elizabeth Nelson, Filip Janku, Siqing Fu

|May 19, 2025
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).

Mohamed A Gouda, Filip Janku, Ying Yuan

|Feb 06, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.

Mohamed A Gouda, Zihan Wei, Jordi Rodon

|Mar 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Filip Janku, Grace M Choong, Mateusz Opyrchal

|Dec 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.

Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul

Pageof 5

Frequent Collaborators

11 joint publications

David S Hong

7 joint publications

Funda Meric-Bernstam

7 joint publications

Vivek Subbiah

7 joint publications

Aung Naing